Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

The Comirnaty vaccine received a positive opinion from the EMA’s CHMP for children five to under 12 years of age. 

EMA Recommends Pfizer and BioNTech’s COVID-19 Vaccine for Children 

Novavax has announced that EMA has started its review of a conditional marketing authorization application for its COVID-19 vaccine, NVX-CoV2373.

EMA Begins Evaluation of Novavax COVID-19 Vaccine Marketing Authorization Application

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Richard Denk, Senior Consultant Aseptic Processing and Containment, SKAN AG, discusses the evolution of aseptic processing with a particular focus on isolators.

Evolution of Aseptic Processing: INTERPHEX Keynote Part 2

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Gernot Warnke, Head of R&D, JRS Pharma, spoke about excipients and how these relate to feeding in batch and continuous manufacturing. 

Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 5

Sharon Nowak, Business Development Manager, Coperion K-Tron USA Food & Pharmaceutical Industries spoke about feeding equipment in solid-dosage drug manufacturing.

Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 4

Feliza Mirasol is the science editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2

Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University, spoke about trends in continuous manufacturing of OSD drugs.

Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 3

Johannes Khinast, PhD, Institute for Process and Particle Engineering in the Research Center Pharmaceutical Engineering (RCPE) at the Graz University of Technology in Austria, spoke about continuous manufacturing of OSD drugs.

Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 2

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 1 

Dave DiProspero, director of Pharmaceutical Process Technology at CRB, spoke about equipment trends in solid-dosage drug manufacturing.